Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hematologic malignancies in pregnancy.

Timothy J Hurley1, James V McKinnell, Mehraboon S Irani

  • 1Division of Maternal and Fetal Medicine, Department of Obstetrics and Gynecology, University of New Mexico Health Science Center, 2211 Lomas Boulevard, Albuquerque, NM 87131, USA. thurley@salud.unm.edu

Obstetrics and Gynecology Clinics of North America
|November 29, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Drug-induced thrombocytopenia after SARS CoV-2 monoclonal antibody administration treated with plasma exchange.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2026
Same author

Caplacizumab for treatment of thrombotic thrombocytopenic purpura in a patient with anaphylaxis to fresh-frozen plasma.

Transfusion·2020
Same author

Risk of hypotensive reactions is increased when using partial saline replacement for therapeutic plasma exchange.

Journal of clinical apheresis·2019
Same author

A Platelet Factor 4-Dependent Platelet Activation Assay Facilitates Early Detection of Pathogenic Heparin-Induced Thrombocytopenia Antibodies.

Chest·2017
Same author

IVIg for Treatment of Severe Refractory Heparin-Induced Thrombocytopenia.

Chest·2017
Same author

Red cell exchange to mitigate a delayed hemolytic transfusion reaction in a patient transfused with incompatible red blood cells.

Journal of clinical apheresis·2016
Same journal

Bridging Science and Practice in Gender-Affirming Care: A Compendium for Gynecologists.

Obstetrics and gynecology clinics of North America·2026
Same journal

Evidence, Clinical Expertise, and Research Gaps in Gender-Affirming Care.

Obstetrics and gynecology clinics of North America·2026
Same journal

Evaluation and Management of the Pediatric Gender-Diverse Patient.

Obstetrics and gynecology clinics of North America·2026
Same journal

Expanding Access to Cervical Cancer Screening for Transgender and Nonbinary Individuals.

Obstetrics and gynecology clinics of North America·2026
Same journal

Updates on Breast Cancer Screening and Special Considerations for Transgender Men and Women.

Obstetrics and gynecology clinics of North America·2026
Same journal

Contraceptive Needs of the Transmasculine Patient.

Obstetrics and gynecology clinics of North America·2026
See all related articles

Hematologic cancers during pregnancy are rare but serious. Prompt diagnosis and multidisciplinary care are crucial, and chemotherapy appears safe for infants exposed in utero.

Area of Science:

  • Obstetrics and Gynecology
  • Hematology
  • Oncology

Background:

  • Hematologic malignancies are uncommon during pregnancy.
  • Delayed diagnosis or treatment can significantly impact maternal and fetal outcomes.
  • Requires a high index of suspicion for unexplained lymphadenopathy or constitutional symptoms.

Purpose of the Study:

  • To highlight the importance of early recognition and management of hematologic cancers in pregnant patients.
  • To emphasize the need for a multidisciplinary approach involving oncology, pediatrics, and obstetrics.
  • To address the concerns regarding chemotherapy use during pregnancy.

Main Methods:

  • Review of clinical presentation and diagnostic considerations for hematologic malignancies in pregnancy.

Related Experiment Videos

  • Discussion of multidisciplinary management strategies.
  • Summary of outcomes for infants exposed to chemotherapy in utero.

    • Main Results:

    • Early detection and a coordinated team approach are vital for optimal outcomes.
    • Multiagent chemotherapy is often necessary for maternal survival.
    • Infants exposed to chemotherapy in utero have shown no significant long-term adverse effects.

    Conclusions:

    • Obstetric providers must maintain a high index of suspicion for hematologic malignancies.
    • Multidisciplinary collaboration is essential for effective management.
    • Current evidence suggests chemotherapy in utero is relatively safe for fetal development.